Compare SHO & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHO | GENB |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2004 | 2026 |
| Metric | SHO | GENB |
|---|---|---|
| Price | $11.31 | $13.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $11.96 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.0M |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $1,115,167,000.00 | N/A |
| Revenue This Year | $2.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.69 | $11.00 |
| 52 Week High | $12.07 | $22.67 |
| Indicator | SHO | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 43.15 |
| Support Level | $10.99 | $14.89 |
| Resistance Level | $11.19 | $15.05 |
| Average True Range (ATR) | 0.17 | 0.88 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 57.58 | 9.23 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.